Trial Profile
Comparison of new paediatric fixed-dose combination of lamivudine/abacavir dispersible tablets with Epzicom®
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2015
Price :
$35
*
At a glance
- Drugs Lamivudine/abacavir (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Mylan
- 16 Sep 2015 New trial record
- 22 Jul 2015 Results presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.